Admin_Adham
Denali-Sanofi Scraps Mid-stage Study for Multiple Sclerosis Drug
(Reuters) -Denali Therapeutics said on Thursday its partner Sanofi has discontinued a mid-stage study testing their experimental drug to treat multiple sclerosis as it failed to meet the main and secondary study goals.
Multiple sclerosis is a debilitating neurological condition where the immune system degrades the protective covering of nerves.
The drug candidate, oditrasertib, co-developed by Sanofi and Denali, had failed to meet the main goal another mid-stage study testing it as a treatment for amyotrophic lateral sclerosis, a fatal neurodegenerative disease.
Sanofi and Denali had entered into a partnership in 2018, in which Sanofi agreed to conduct trials to test therapies developed by Denali for neurological and inflammatory diseases.
(Reporting by Mariam Sunny in Bengaluru; Editing by Alan Barona)
